definiens: shall mean the Patent Rights Controlled by [COMPANY] or its Affiliates ( a ) as of theEffective Date, ( b ) at any time during the [ * * ] period following the Effective Date, ( c ) during the term of this Agreement, ifsuch Patent Rights Controlled by [COMPANY] or its Affiliates are licensed from Sirna Therapeutics, Inc., or ( d ) at any time ifsuch Patent Rights are within the [COMPANY] Collaboration Target Specific Intellectual Property and not assigned to Takedapursuant to Section 6.3(b ), in-5- each case that Cover RNAi technology, products or processes ( including compositions, methods and uses of RNAiCompounds ), including : ( i ) the general structure, architecture, or design of RNAi Compounds ; ( ii ) chemical modificationsof such RNAi Compounds ( including any modifications to the bases, sugars or internucleoside linkages, nucleotidemimetics, conjugates and any end modifications ) ; ( iii ) all uses or applications of RNAi Compounds referred to in theforegoing clause ( i ) or ( ii ) ; and ( iv ) manufacturing techniques for RNAi Compounds referred to in the foregoing clauses(i ) and ( ii ) ; but excluding ( A ) [COMPANY] [ * * ] Specific Patent Rights, or ( B ) Delivery Patent Rights . For purposes of clarity, Broad RNAi Patent Rights shall not include Patent Rights to the extent specifically and solely related to and useful formicroRNAs, microRNA antagonists, or microRNA mimics